StockData
Lexaria Bioscience Corp. logo

Lexaria Bioscience Corp. (LEXX) stock

LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026Score 8/30
$4.18−0.23 (-5.22%)

Close on Nov 17, 2026Market cap $103.61MP/E –Yield –

Lexaria Bioscience price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Lexaria Bioscience's price to sales ratio was 445.9× on Oct 30, 2026, against 415.6× a year earlier.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Oct 30, 2026445.9×+189.5
2025Dec 31, 2025256.4×−139.4
2023Sep 29, 2023395.8×−83.2
2021Dec 31, 2021479.0×–

More Lexaria Bioscience figures

See a number that looks wrong?